242 filings
Page 4 of 13
8-K
l3nln351g6 l3lzl281
13 Aug 21
Diffusion Pharmaceuticals Reports Q2 Financial Results
4:30pm
8-K
b9rgrdf k8hlwtk
30 Jun 21
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
4:33pm
8-K
jz1jiz
29 Jun 21
Submission of Matters to a Vote of Security Holders
9:05am
8-K
w5yd3bm378q93dfd8
12 May 21
Diffusion Pharmaceuticals Reports First Quarter Financial Results
7:30am
8-K
ojgc80vbr5eg
7 May 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
8b2g 09lce
25 Mar 21
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
5:20pm
8-K
4cp6q8zewhip
18 Mar 21
Regulation FD Disclosure
4:14pm
8-K
7dm902im8aq5wbf11
17 Mar 21
Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update
4:36pm
8-K
cdjklwap
8 Mar 21
Regulation FD Disclosure
4:10pm
8-K
a6vp 1nrz
18 Feb 21
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
4:52pm
8-K
7sp rth8n
16 Feb 21
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
8:10am
8-K
uy1zk9yjn
12 Feb 21
Note Regarding Forward-looking Statements
8:19am
8-K
yk20 dh8v0roj
26 Jan 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:50pm
8-K
rkm3gma4d71ctt9q
8 Jan 21
Regulation FD Disclosure
4:07pm
8-K
jlhoq5t8s
14 Dec 20
Regulation FD Disclosure
11:32am
8-K
jtx vqy8xljj
12 Nov 20
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
4:57pm
8-K
a2gl ni482597fb
20 Oct 20
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
5:30pm
8-K
nt15jpno8f2220
9 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:16pm
8-K
qxit9hs2m309s1tg
25 Sep 20
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
4:57pm
8-K
c8bqcqmaubn
15 Sep 20
Regulation FD Disclosure
2:50pm